Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT ID: NCT06165341
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
50 participants
INTERVENTIONAL
2024-03-01
2028-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971
A Study of Belcesiran in Patients With AATLD
NCT04764448
A Study About Fazirsiran in People With and Without Liver Problems
NCT05891158
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
NCT02227459
FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
NCT03820934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fazirsiran 200 mg
Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.
Fazirsiran Injection
Fazirsiran will be injected subcutaneously.
Placebo
Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.
Placebo
Fazirsiran matching placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fazirsiran Injection
Fazirsiran will be injected subcutaneously.
Placebo
Fazirsiran matching placebo.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
* The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
* The participant, of any sex, is aged 18 to 75 years, inclusive.
* The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
* The participant's liver biopsy core samples collected as per protocol requirements.
* The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
* The participant has a pulmonary status that meets the protocol requirements.
* It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
* Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
* An adult participant must have a body mass index (BMI) between 18 and 39 kilogram per meter square (kg/m\^2), inclusive.
* The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
* The participant is a nonsmoker.
* If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to \[\<=10\] milligrams per day \[mg/d\] or its equivalent), the doses of the participant's medications must have remained unchanged for greater than or equal to (\>=) 4 weeks before screening.
* The participant must have suitable venous access for blood sampling.
* A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
* The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.
Exclusion Criteria
* The participant has a history of liver decompensating events.
* The participant has a history of varices based on a previous esophagogastroduodenoscopy.
* The participant has portal vein thrombosis.
* The participant has undergone a prior trans-jugular portosystemic shunt procedure.
* The participant has evidence of other forms of chronic liver diseases.
* The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (\>) 1 year may be enrolled after approval by the medical monitor.
* The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
* The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
* The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
* The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months before screening. The participant may be screened earlier based on principal investigator (PI) assessment of clinical recovery and return to baseline pulmonary function in discussion with the medical monitor.
* The participant has a history of frequent pulmonary exacerbations (\>=2 moderate or severe exacerbations within 52 weeks before screening).
* The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
* The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease \[COPD\] exacerbation) or CPAP for obstructive sleep apnea.
* The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
* The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid \[RNA\] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
* The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
* The participant has a history of torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.
* The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than \[\<\] 20 percent \[%\]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
* The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
* The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
* The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
* The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
* The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
* The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
* The participant has donated \>=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
* The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
* The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
* This participant is unable to return for all scheduled study visits.
* The participant has known or suspected coronavirus disease 2019 (COVID-19) that, in the opinion of the sponsor and investigator, does not resolve during screening. Positive antibody testing for COVID-19 without other evidence of current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infection may be temporarily delayed at the discretion of the sponsor and investigator. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.
* The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
* The participant takes or is required to take excluded medications.
* The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Mayo Clinic - PPDS
Phoenix, Arizona, United States
University of Arizona Thomas D. Boyer Liver Institute
Tucson, Arizona, United States
University of California San Diego
La Jolla, California, United States
UCLA Pulmonary and Critical Care
Los Angeles, California, United States
University of California Benioff Children's Hospital
San Francisco, California, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Schiff Center for Liver Diseases/University of Miami
Miami, Florida, United States
Indiana University School of Medicine-Indianapolis
Indianapolis, Indiana, United States
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, United States
Boston Medical Center
Boston, Massachusetts, United States
University of Michigan Hospital - 1500 E Medical Center Dr
Ann Arbor, Michigan, United States
Henry Ford Health System
Novi, Michigan, United States
Mayo Clinic PPDS
Rochester, Minnesota, United States
NYU Langone Medical Center
New York, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Texas Liver Institute American Research Corporation
San Antonio, Texas, United States
Bon Secours St. Mary's Hospital
Newport, Virginia, United States
LKH-Universitätsklinikum Graz
Graz, , Austria
KABEG - Klinikum Klagenfurt Am Wörthersee
Klagenfurt, , Austria
UZ Antwerpen
Antwerp, , Belgium
UZ Leuven
Leuven, , Belgium
Inspiration Research Limited
Toronto, Ontario, Canada
Hôpital de La Croix Rousse
Lyon, , France
Hopital PONTCHAILLOU CHU de Rennes
Rennes, , France
Hôpital Paul Brousse
Val-de-Marne, , France
Universitätsklinikum der RWTH Aachen
Aachen, , Germany
Charité - Campus Virchow-Klinikum
Berlin, , Germany
Hannover Medical School
Hanover, , Germany
Universitätsklinikum Tübingen
Tübingen, , Germany
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
ID Clinic Arkadiusz Pisula
Mysłowice, , Poland
CCA Hospital Braga
Braga, , Portugal
Hospital Dr. Nélio Mendonça
Funchal, , Portugal
Centro Hospitalar de Universitário de Santo António E.P.E
Porto, , Portugal
Hospital Universitario Virgen del Rocio - PPDS
Seville, , Spain
Karolinska Universitetssjukhuset Huddinge
Huddinge, , Sweden
Universitätsspital Bern
Bern, , Switzerland
King's College Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Site Contact
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504198-19-00
Identifier Type: CTIS
Identifier Source: secondary_id
TAK-999-3002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.